The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
PrECOG 0905 trial: Gilteritinib vs midostaurin + intensive chemotherapy in patients with newly diagnosed FLT3-mutated AML
|
Gilteritinib, a highly potent selective FLT3 inhibitor, is approved as monotherapy for the treatment of relapsed/refractory FLT3-mutated AML. At the 66th ASH Annual Meeting and Exposition, Luger presented the findings of the phase II PrECOG 0905 trial (NCT03836209), evaluating the efficacy of gilteritinib vs midostaurin in combination with intensive chemotherapy in patients with newly diagnosed FLT3-mutated AML.1 Eligible patients (N = 177) were stratified by mutation type and randomized 1:1 to receive cytarabine + daunorubicin + gilteritinib (n = 90) or cytarabine + daunorubicin + midostaurin (n = 87) during induction and consolidation.1 The primary endpoint was the FTL3-mutation MRD-negative CRc rate post-induction. Secondary endpoints included CRc, MRD negativity (10−3) by flow cytometry, and survival.1 |
| Key learnings |
| The CRc (85.6% vs 72.4%; p = 0.042) and MRD-negativity (10−3) rates (64.4% vs 59.8%) were higher in the gilteritinib arm compared to the midostaurin arm. |
| The gilteritinib arm had a lower post-induction FLT3-mutation CRc rate than the midostaurin arm (40.0% vs 47.1%; p = 0.366). |
| TRAEs were reported in 82.0% of patients receiving gilteritinib vs 75.0% of patients receiving midostaurin, with SAEs reported in 11% and 10% of patients, respectively. |
| Among patients who achieved CRc and were FLT3-mutated MRD-positive at the end of induction (n = 27), 83.3% of patients receiving gilteritinib and 44.4% of patients receiving midostaurin were MRD-negative post-consolidation C1 (p = 0.072). |
| Findings from the PrECOG 0905 trial suggest that post-induction gilteritinib vs midostaurin plus intensive chemotherapy resulted in improved CRc rate but not mutational MRD-negative rate in patients with newly diagnosed FLT3-mutated AML. |
Abbreviations: AML, acute myeloid leukemia; ASH, American Society of Hematology; C1, first cycle; CRc, composite complete remission; MRD, measurable residual disease; SAE, serious adverse event; TRAE, treatment-related adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content